Adult Dosing
Hypertension
- Start 100 mg PO bid with or without a diuretic
- Titrate: Increase 100 mg PO bid q2-3 days until optimum response is reached
- Usual 200-400 mg bid. [Max: 2400 mg/day]
Pediatric Dosing
- Safety and effectiveness in pediatric patients have not been established
Hypertension [Non-FDA Approved]
- Initial: 4 mg/kg/24 hr divided bid. May increase up to 40 mg/kg/24 hr
[Outline]
- Therapy may cause hepatic necrosis and death after both short- and long-term treatment. Therefore periodically perform hepatic laboratory tests. Suspend therapy if the patient has laboratory evidence of liver injury or jaundice
- Therapy may cause depressed myocardial contractility and precipitation of more severe cardiac failure. Therefore administer cautiously in patients with a history of heart failure who are well compensated. Avoid use in CHF patients
- Abrupt cessation of therapy may cause exacerbations of angina pectoris and myocardial infarction in patients with coronary artery disease
- It should not be used in nonallergic bronchospasm (e.g., Chronic Bronchitis and Emphysema) patients
- Use caution when administering labetalol to patients with pheochromocytoma to avoid paradoxical hypertensive responses
- Adjust the dose of antidiabetic drugs as therapy reduces the release of insulin in response to hyperglycemia
- Avoid use during major surgery as several deaths have occurred when labetalol hydrochloride injection was used during surgery
- Therapy may cause Intraoperative Floppy Iris Syndrome (IFIS). The patient’s ophthalmologist should be prepared for possible modifications to the surgical technique
Cautions: Use cautiously in
- Hepatic impairment
- Renal impairment
- Hypotension
- Diabetes mellitus
- PVD
- Respiratory difficulties
- Bronchospastic disease
- Thyrotoxicosis
- Pheochromocytoma
- Elderly patients
Pregnancy Category:C
Breastfeeding: Labetolol is excreted in breast milk in small amounts. Amounts ingested by the infant are small and would not be expected to cause any adverse effects in full-term breastfed infants; use alternate agents in preterm infants. This information is based on LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT). This drug is compatible and considered safe with breastfeeding based upon data from AAP Policy Guidelines (available at http://aappolicy.aappublications.org/cgi/content/full/pediatrics;108/3/776 last accessed 10 February 2011). Manufacturer advises caution.
Pricing data from www.DrugStore.com in U.S.A.
- Trandate 200 MG TABS [Bottle] (PROMETHEUS)
60 mg = $66.99
180 mg = $195.97
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.
